Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats

被引:59
|
作者
Lourenco, Andre P. [1 ]
Roncon-Albuquerque, Roberto, Jr. [1 ]
Bras-Silva, Carmen [1 ]
Faria, Bernardo [1 ]
Wieland, Joris [1 ]
Henriques-Coelho, Tiago [1 ]
Correia-Pinto, Jorge [1 ]
Leite-Moreira, Adelino F. [1 ]
机构
[1] Univ Porto, Fac Med, Dept Physiol, P-4100 Oporto, Portugal
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2006年 / 291卷 / 04期
关键词
gene expression; myocardial contractility; neuroendocrine stimulation; endothelin-1; heart;
D O I
10.1152/ajpheart.01004.2005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol 291: H1587-H1594, 2006. First published May 5, 2006; doi: 10.1152/ajpheart. 01004.2005. - In monocrotaline (MCT)-induced pulmonary hypertension (PH), only the right ventricle (RV) endures overload, but both ventricles are exposed to enhanced neuroendocrine stimulation. To assess whether in long-standing PH the left ventricular (LV) myocardium molecular/contractile phenotype can be disturbed, we evaluated myocardial function, histology, and gene expression of autocrine/paracrine systems in rats with severe PH 6 wk after subcutaneous injection of 60 mg/kg MCT. The overloaded RV underwent myocardial hypertrophy (P < 0.001) and fibrosis (P = 0.014) as well as increased expression of angiotensin-converting enzyme (ACE) (8-fold; P < 0.001), endothelin-1 (ET-1) (6-fold; P < 0.001), and type B natriuretic peptide (BNP) (15-fold; P < 0.001). Despite the similar upregulation of ET-1 (8-fold; P < 0.001) and overexpression of ACE (4-fold; P < 0.001) without BNP elevation, the nonoverloaded LV myocardium was neither hypertrophic nor fibrotic. LV indexes of contractility (P < 0.001) and relaxation (P = 0.03) were abnormal, however, and LV muscle strips from MCT-treated compared with sham rats presented negative (P = 0.003) force-frequency relationships (FFR). Despite higher ET-1 production, BQ-123 (ETA antagonist) did not alter LV MCT-treated muscle strip contractility distinctly (P = 0.005) from the negative inotropic effect exerted on shams. Chronic daily therapy with 250 mg/kg bosentan (dual endothelin receptor antagonist) after MCT injection not only attenuated RV hypertrophy and local neuroendocrine activation but also completely reverted FFR of LV muscle strips to positive values. In conclusion, the LV myocardium is altered in advanced MCT-induced PH, undergoing neuroendocrine activation and contractile dysfunction in the absence of hypertrophy or fibrosis. Neuroendocrine mediators, particularly ET-1, may participate in this functional deterioration.
引用
收藏
页码:H1587 / H1594
页数:8
相关论文
共 44 条
  • [21] CONTRIBUTION OF ENDOGENOUS ENDOTHELIN-1 TO THE PROGRESSION OF CARDIOPULMONARY ALTERATIONS IN RATS WITH MONOCROTALINE-INDUCED PULMONARY-HYPERTENSION
    MIYAUCHI, T
    YORIKANE, R
    SAKAI, S
    SAKURAI, T
    OKADA, M
    NISHIKIBE, M
    YANO, M
    YAMAGUCHI, I
    SUGISHITA, Y
    GOTO, K
    CIRCULATION RESEARCH, 1993, 73 (05) : 887 - 897
  • [22] Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response
    Yang, Jia-mei
    Zhou, Ru
    Zhang, Min
    Tan, Huan-ran
    Yu, Jian-qiang
    MOLECULES, 2018, 23 (06):
  • [23] Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats
    Nishida, Masahiro
    Hasegawa, Youichi
    Tanida, Izumi
    Nakagawa, Erika
    Inaji, Haruka
    Ohkita, Mamoru
    Matsumura, Yasuo
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 614 (1-3) : 70 - 76
  • [24] Adipose-derived regenerative cell therapy inhibits the progression of monocrotaline-induced pulmonary hypertension in rats
    Eguchi, Masamichi
    Ikeda, Satoshi
    Kusumoto, Saburo
    Sato, Daisuke
    Koide, Yuji
    Kawano, Hiroaki
    Maemura, Koji
    LIFE SCIENCES, 2014, 118 (02) : 306 - 312
  • [25] Changes of Gene Expression after Bone Marrow Cell Transfusion in Rats with Monocrotaline-Induced Pulmonary Hypertension
    Kim, Kwan Chang
    Lee, Hae Ryun
    Kim, Sung Jin
    Cho, Min-Sun
    Hong, Young Mi
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (06) : 605 - 613
  • [26] Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus
    Atli, Ozlem
    Ilgin, Sinem
    Ergun, Bulent
    Burukoglu, Dilek
    Musmul, Ahmet
    Sirmagul, Basar
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 17 (01) : 8 - 17
  • [27] The Effect of Umbilical Cord Blood Derived Mesenchymal Stem Cells in Monocrotaline-induced Pulmonary Artery Hypertension Rats
    Lee, Hyeryon
    Lee, Jae Chul
    Kwon, Jung Hyun
    Kim, Kwan Chang
    Cho, Min-Sun
    Yang, Yoon Sun
    Oh, Wonil
    Choi, Soo Jin
    Seo, Eun-Seok
    Lee, Sang-Joon
    Wang, Tae Jun
    Hong, Young Mi
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (05) : 576 - 585
  • [28] Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal
    Udovicic, Mario
    Sever, Marko
    Kavur, Lovro
    Loncaric, Kristina
    Barisic, Ivan
    Balenovic, Diana
    Posilovic, Gordana Zivanovic
    Strinic, Dean
    Uzun, Sandra
    Vuletic, Lovorka Batelja
    Sikiric, Suncana
    Skrtic, Anita
    Drmic, Domagoj
    Blagaic, Alenka Boban
    Bencic, Martina Lovric
    Seiwerth, Sven
    Sikiric, Predrag
    BIOMEDICINES, 2021, 9 (07)
  • [29] Gene Expressions of Nitric Oxide Synthase and Matrix Metalloproteinase-2 in Monocrotaline-Induced Pulmonary Hypertension in Rats After Bosentan Treatment
    Koo, Hee Sun
    Kim, Kwan Chang
    Hong, Young Mi
    KOREAN CIRCULATION JOURNAL, 2011, 41 (02) : 83 - 90
  • [30] Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: A potential role for atrogin-1 in smooth muscle
    Paffett, Michael L.
    Lucas, Selita N.
    Campen, Matthew J.
    VASCULAR PHARMACOLOGY, 2012, 56 (1-2) : 64 - 73